153 related articles for article (PubMed ID: 11322651)
41. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.
Liu Q; Zhang H; Zhou G; Xie S; Zou H; Yu Y; Li G; Sun D; Zhang G; Lu Y; Zhong Y
Int J Pharm; 2010 Sep; 397(1-2):122-9. PubMed ID: 20650309
[TBL] [Abstract][Full Text] [Related]
42. Thymosin alpha 1: from bench to bedside.
Garaci E; Favalli C; Pica F; Sinibaldi Vallebona P; Palamara AT; Matteucci C; Pierimarchi P; Serafino A; Mastino A; Bistoni F; Romani L; Rasi G
Ann N Y Acad Sci; 2007 Sep; 1112():225-34. PubMed ID: 17600290
[TBL] [Abstract][Full Text] [Related]
43. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice.
Zhu XL; Chen AF; Lin ZB
J Ethnopharmacol; 2007 May; 111(2):219-26. PubMed ID: 17182202
[TBL] [Abstract][Full Text] [Related]
44. Biodistribution of synthetic thymosin alpha1 in the serum, urine and major organs of mice.
Badamchian M; Mora CA; Baumann CA; Paino JE; Goldstein AL
Int J Immunopharmacol; 1997 Feb; 19(2):59-66. PubMed ID: 9278175
[TBL] [Abstract][Full Text] [Related]
45. Effect of a C-end rule modification on antitumor activity of thymosin α1.
Wang F; Xu C; Peng R; Li B; Shen X; Zheng H; Lao X
Biochimie; 2018 Nov; 154():99-106. PubMed ID: 30096371
[TBL] [Abstract][Full Text] [Related]
46. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo.
Bozza S; Gaziano R; Bonifazi P; Zelante T; Pitzurra L; Montagnoli C; Moretti S; Castronari R; Sinibaldi P; Rasi G; Garaci E; Bistoni F; Romani L
Int Immunol; 2007 Nov; 19(11):1261-70. PubMed ID: 17804687
[TBL] [Abstract][Full Text] [Related]
47. [Effects of thymosin alpha1 on immune effector molecules of mouse].
Li WY; Lu HM; Guo Q; Hu WM; Zhang ZD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):400-4. PubMed ID: 24941805
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity in Swine of Orally Administered Recombinant Lactobacillus plantarum Expressing Classical Swine Fever Virus E2 Protein in Conjunction with Thymosin α-1 as an Adjuvant.
Xu YG; Guan XT; Liu ZM; Tian CY; Cui LC
Appl Environ Microbiol; 2015 Jun; 81(11):3745-52. PubMed ID: 25819954
[TBL] [Abstract][Full Text] [Related]
49. The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: inhibition of helper T-cell induction in vitro.
Varkila K; Hurme M
Immunology; 1983 Mar; 48(3):433-8. PubMed ID: 6219062
[TBL] [Abstract][Full Text] [Related]
50. The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system.
Nishimura Y; Eto M; Maeda T; Hiromatsu K; Nomoto K; Kong YY; Nomoto K
Immunobiology; 1995 Aug; 193(5):420-38. PubMed ID: 8522358
[TBL] [Abstract][Full Text] [Related]
51. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
Jia Z; Feng Z; Tian R; Wang Q; Wang L
Immunopharmacol Immunotoxicol; 2015; 37(4):388-92. PubMed ID: 26250523
[TBL] [Abstract][Full Text] [Related]
52. Effect of synthetic thymic humoral factor (THF-gamma 2) on T cell activities in immunodeficient ageing mice.
Goso C; Frasca D; Doria G
Clin Exp Immunol; 1992 Mar; 87(3):346-51. PubMed ID: 1531947
[TBL] [Abstract][Full Text] [Related]
53. Thymosin α1 and cancer: action on immune effector and tumor target cells.
Garaci E; Pica F; Serafino A; Balestrieri E; Matteucci C; Moroni G; Sorrentino R; Zonfrillo M; Pierimarchi P; Sinibaldi-Vallebona P
Ann N Y Acad Sci; 2012 Oct; 1269():26-33. PubMed ID: 23045967
[TBL] [Abstract][Full Text] [Related]
54. The role of Tα1 on the infective patients after hematopoietic stem cell transplantation.
Ding JH; Wang LL; Chen Z; Wang J; Yu ZP; Zhao G; Chen BA
Int J Hematol; 2013 Feb; 97(2):280-3. PubMed ID: 23307511
[TBL] [Abstract][Full Text] [Related]
55. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H
Front Immunol; 2021; 12():568789. PubMed ID: 34149679
[TBL] [Abstract][Full Text] [Related]
56. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.
Arase Y; Tsubota A; Suzuki Y; Suzuki F; Kobayashi M; Someya T; Akuta N; Hosaka T; Saitoh S; Ikeda K; Kobayashi M; Kumada H
Intern Med; 2003 Oct; 42(10):941-6. PubMed ID: 14606705
[TBL] [Abstract][Full Text] [Related]
57. Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo.
Shen X; Wang L; Xu C; Yang J; Peng R; Hu X; Wang F; Zheng H; Lao X
Int Immunopharmacol; 2019 Sep; 74():105662. PubMed ID: 31220695
[TBL] [Abstract][Full Text] [Related]
58. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.
Lao X; Liu M; Chen J; Zheng H
PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262
[TBL] [Abstract][Full Text] [Related]
59. Immunological enhancement with a low dose of cyclophosphamide in aged mice.
Ishiyama N; Utsuyama M; Kitagawa M; Hirokawa K
Mech Ageing Dev; 1999 Nov; 111(1):1-12. PubMed ID: 10576603
[TBL] [Abstract][Full Text] [Related]
60. Enhancement of helper and suppressor T cell activities by thymosin alpha 1 injection in old mice.
Frasca D; Adorini L; Doria G
Immunopharmacology; 1985 Aug; 10(1):41-9. PubMed ID: 2932410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
